RxDoctor Payments Data

David Rosenbaum, MD

Cardiovascular Disease · Colorado Springs, CONPI 1346284601

Payments from drug & device makers

$6,072in general payments, 2019–2025

Across 8 payments — averaging $758.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • Medtronic$776
  • Abiomed$102
  • Dexcom, Inc.$25
  • Boston Scientific$22

What the payments were for

  • Travel & lodging$67673%
  • Food & beverage$24927%

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim1$5,147
Medtronic4$776
Abiomed1$102
Dexcom, Inc.1$25
Boston Scientific1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,072 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$228,587
Medicare patients
1,377
Services billed
3,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban442$608,373
VyndamaxTafamidis12$304,434
Repatha SureclickEvolocumab131$165,146
EntrestoSacubitril/Valsartan54$98,961
XareltoRivaroxaban52$60,065
JardianceEmpagliflozin35$48,523
Praluent PenAlirocumab31$42,340
MultaqDronedarone Hcl14$24,461
Dabigatran EtexilateDabigatran Etexilate Mesylate33$13,536
PradaxaDabigatran Etexilate Mesylate31$9,791
Valsartan261$8,679
Rosuvastatin Calcium711$7,965
Flecainide Acetate95$7,161
Metoprolol Succinate414$5,532
Atorvastatin Calcium511$5,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Pradaxa$5,147$58,31466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →